Business Wire

Biolog-id LLC Partners with LifeServe Blood Center to Implement Cutting-Edge Blood Product Inventory Management Ecosystem

13.1.2020 16:00:00 EET | Business Wire | Press release

Share

Biolog-id LLC, a world leader in connected solutions for blood and other high value health products, announced today that LiveServe Blood Center, the leading provider of blood products in Iowa, Nebraska, and South Dakota, will implement Biolog-id’s cutting-edge technology solution in its blood supply chain. The technology solution provides real-time visibility into blood product location and movement, providing actionable data to streamline inventory and improve efficiencies to maximize return on donation. Patients, donors, and staff across LifeServe’s enterprise will benefit from the actionable insights provided by a digitally visible supply chain.

“LifeServe Blood Center is the perfect partner for Biolog-id. They embrace change and innovation. They are constantly seeking new ways to deploy technology to reduce costs, improve quality, and impact patient outcomes,” said Patrick Conway, Director of Sales Biolog-id LLC. “Biolog-id’s unique solution combines hardware, software, consumables and data analytics is a great platform to help deliver those desired results.”

“Our partnership with Biolog-id LLC builds on our heritage of continuously innovating and improving to address the changing needs of patients, hospitals, and donors to ensure the sustainability of our blood supply,” said Stacy Sime, CEO of Lifeserve Blood Center.“ By providing us rich, real-time insights about our blood inventory, the technology ecosystem we are deploying has the opportunity to provide our organization, our hospitals and the patients who receive life-saving blood, multiple channels of value.”

“There is a crucial need to evolve processes in healthcare to achieve higher levels of efficiency and scale, yielding positive results across the healthcare industry,” said Troy L. Hilsenroth, CEO Biolog-id LLC. “Our goal is to facilitate this evolution in an effort to provide everyone with effective, reliable products and services that meet the highest standards of quality and have adaptability for future uses.”

Enabling a new standard of care of how high value products in healthcare are distributed, stored, utilized, and tracked are center to Biolog-id LLC’s vison.

About Biolog-id

Biolog-id has developed a patented smart solution for the management and traceability of sensitive, high-value health products throughout the hospital supply chain to ensure safe delivery from donor to patient. Biolog-id operates in North America, Europe, Middle East, India and Asia Pacific region and has more than 100 employees worldwide. Staff numbers should double in the next three years. The Biolog-connect® solution is protected by more than 100 international patents.

Biolog-id is owned by its founder and the Xerys Funds. www.biolog-id.com

About LifeServe Blood Center

LifeServe Blood Center is a non-profit, community-based blood center that has served the needs of local hospitals and patients in our regions since 1963. As one of the 15 largest blood centers in the country, LifeServe Blood Center is the SOLE provider of blood and blood products to more than 120 hospitals located across Iowa, Nebraska, and South Dakota. LifeServe is committed to saving lives by providing premier service to volunteer blood donors and access to a safe, quality blood supply for hospitals and patients. Company URL: https://www.lifeservebloodcenter.org/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Amit Mayer, amit.mayer@biolog-id.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HPE Takes Licence to Patents Offered Through the Sisvel Wi-Fi Multimode Pool8.4.2026 11:00:00 EEST | Press release

Hewlett Packard Enterprise (HPE) has become the latest company to take a licence to the patents offered through the recently launched Sisvel Wi-Fi Multimode pool. It joins Sony Group Corporation, Huawei, Panasonic, Philips and ZTE as a licensee of the programme. The latter four are also licensors, along with KPN, Mitsubishi Electric, Orange, Aegis 11 SA (a Sisvel affiliate), SK Telecom and Wilus. HPE is a major presence in the global WLAN market and is a leading manufacturer of both consumer and enterprise routers. The deal with Sisvel was reached on an amicable basis. The Sisvel Wi-Fi Multimode pool is the successor programme to the Sisvel Wi-Fi 6 patent pool. Over a three-year period, this closed agreements with nearly 40 companies, including Acer, Netgear, Cisco and HP. Covering Wi-Fi 7 as well as 6, the Multimode programme offers an efficient way to access essential Wi-Fi rights for years to come. “We are delighted to welcome Hewlett Packard Enterprise as the latest licensee of the

Zyxel and Openreach Team Up to Reduce Plastic Waste in Full Fibre Installations8.4.2026 11:00:00 EEST | Press release

A new partnership between Zyxel Communications and Openreach is helping to cut plastic and packaging waste from the UK’s Full Fibre rollout - by deploying re-cycled ‘modems’ to connect customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408766604/en/ Openreach - GPON ONT Zyxel is deploying a range of new Optical Network Terminals (ONTs) - the wall-mounted box of electronics that converts optical signals into electrical ones used by household devices - with re-engineered casings made from 95 per cent recycled plastic.1 Openreach engineers have already installed half a million of Zyxel’s sustainable ONTs and the network provider expects to install even more this year as customers upgrade to Full Fibre - the UK’s most reliable broadband technology. The GPON2 devices use recycled plastic in their construction and arrive in zero‑plastic minimal packaging made from recycled materials. Openreach is working with Zyxel and o

Jeito Capital Hits Record $1.2 Billion (€1 Billion) 1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients8.4.2026 09:15:00 EEST | Press release

Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, today announces the final closing of its second fund Jeito II, exceeding its target at $1.2billion (above €1billion)1,2, and marking a new major milestone for European Biopharma investment. With this new fund, Jeito has now tripled its assets under management to €1.6 billion, following the closing in 2021 of fund Jeito I at $630 million (€534 million) and reinforces its position as a leading fully independent European Biopharma investor. Jeito II will continue the strategy established with Jeito I: selectively identifying and backing 15 to 20 of the most promising clinical stage Biopharma companies, primarily in Europe, developing breakthrough therapies for severe diseases with high unmet medical needs and accelerating the development path and future market access. This fundraising allows Jeito to increase the average size of future investments in portfolio companies up to €150 million, thus drivi

Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics8.4.2026 08:00:00 EEST | Press release

Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering. Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history. The reintroduction of Synocrom™ also builds on Croma-Pharma’s long-standing expertise in the development and manufacturi

Murata Begins Mass Production of Seven Automotive MLCCs with World-leading Capacitance for Their Rated Voltage and Size, Supporting Stable Operation of In-vehicle Systems and Greater Design Flexibility8.4.2026 05:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun mass production of seven AEC-Q200-qualified multilayer ceramic capacitors (MLCCs) that achieve the world’s largest capacitance for a given rated voltage and size*, supporting stable operation of in-vehicle systems and greater design flexibility. Five parts in the GCM series are rated at 2.5-4 Vdc, targeting IC peripheral circuits in advanced driver assistance systems (ADAS) and autonomous driving (AD) applications. The remaining two MLCCs are rated at 25 Vdc for in-vehicle power line applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407486750/en/ [Murata Manufacturing Co., Ltd.] Seven automotive MLCCs In recent years, as ADAS and AD technologies advance, the number and performance level of systems installed in vehicles have continued to increase. As a result, demand for higher capacitance low-voltage MLCCs used around ICs has grown to e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye